OpGen expects to begin clinical validation studies for the AMR Gene Panel u5.47 for complicated urinary tract infections in Q4.
For the three months ended Sept. 30, the firm reported total revenues of $190.2 million, compared to $177.5 million in Q1 2017, beating the consensus Wall Street estimate.
The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.
The partnership combines sequencing with phenotype information to help diagnose patients with rare diseases.
The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.
The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.
Pathoquest will compare its iDtect blood test with standard testing methods to identify microbes causing infections in patients with febrile neutropenia.
Fulgent missed the consensus Wall Street estimates on the top and bottom lines. Its CEO said the firm continues to invest in technology and in streamlining its operations.
Qiagen reported third quarter revenues of $364.0 million, up from $338.7 million a year ago and just above analysts' average estimate of $363.3 million.
The genomic testing company's total revenues were down to $17.5 million in the quarter, although its genomic testing volume increased 14 percent.
The genetic testing firm posted revenues of $18.1 million for the quarter, compared with $6.3 million for the year-ago period.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
This is the first US Food and Drug Administration approval for a drug based solely on data from a basket study.
Participants in the pilot will begin developing the capabilities required for the planned data commons, including making data transparent and interoperable.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
The new agreement between the two companies commits to expanding the clinical genetic testing market in Turkey and is part of a global expansion for BGI.
According to the Federal Register notice, after a first time FDA marketing authorization, manufacturers can commercialize new GHR tests without additional review.
The new funding comes from life sciences investment firm Perceptive Advisors. Home Care Assistance CEO Lily Sarafan has also joined Counsyl's board.
Researchers at Aarhus will use Natera's liquid biopsy assay to monitor colorectal cancer patients after surgery and chemotherapy.
Last week, GenomeWeb's readers were most interested in Danaher's acquisition of UK-based informatics firm IDBS.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The revenue increase was driven by higher test volumes in its reproductive health segment and improved test reimbursement across all segments.
An analysis of new and available liver cancer genomes led to 10 mutational signatures and six structural rearrangement signatures in hepatocellular carcinoma.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.